Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06227377 · ClinicalTrials.gov registry record · Phase 1
QTX3034 in Patients With KRAS G12D Mutation
A Phase 1 study of Solid Tumors, sponsored by Quanta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 14
- Study locations
NCT06227377 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Quanta Therapeutics. The registered enrollment target is 250 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (12% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT06227377, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Quanta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 14
- Study locations
Study Summary
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3034
Study Locations (14)
Florida
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
New York
- NYU Langone Health - New York
- Montefiore Medical Center - The Bronx
Texas
- MD Anderson - Houston
- START San Antonio, LLC - San Antonio
California
- UCLA Hematology/Oncology - Los Angeles
Colorado
- Sarah Cannon Research Institute (SCRI) - Denver
Connecticut
- Yale Cancer Center - New Haven
North Carolina
- Duke University - Durham
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06227377
The ClinicalTrials.gov registry entry for NCT06227377 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (12% lower). The listed sponsor is Quanta Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06227377 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Florida, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06227377 about?
NCT06227377 is a clinical study titled "QTX3034 in Patients With KRAS G12D Mutation". Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06227377?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-02-05. Estimated completion is 2027-04-01.
What conditions does trial NCT06227377 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06227377?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3034 (DRUG).
Who is sponsoring clinical trial NCT06227377?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06227377 being conducted?
This trial has 14 study locations across California, Colorado, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.